Hyperenhanced rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: A histological indication of the presence of kupffer cells

Oncology (Switzerland)

Volumn 89, Issue , 2015, Pages 33-41

  Tochio, Hitoshi ^a   Sugahara, Masafumi ^a   Imai, Yukihiro ^a   Tei, Hiroshi ^a   Suginoshita, Yoshiyuki ^a   Imawsaki, Nobuhiro ^a   Sasaki, Ichiro ^a   Hamada, Michio ^a   Minowa, Kazushi ^a   Inokuma, Tetsuo ^a   Kudo, Masatoshi ^b  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD8 positive T cell; Contrast enhanced ultrasonography; Kupffer cell; Liver cancer; Programmed cell death 1 antibody; Sonazoid

Indexed keywords

CD68 ANTIGEN; PERFLUBUTANE; CONTRAST MEDIUM; FERRIC ION; IRON; OXIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HEPATECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; KUPFFER CELL; LIVER CANCER; LIVER FIBROSIS; LIVER METASTASIS; LIVER NECROSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; RADIOLOGICAL PARAMETERS; CANCER STAGING; FOLLOW UP; IMAGE ENHANCEMENT; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY; TISSUE DISTRIBUTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HUMANS; IMAGE ENHANCEMENT; IRON; KUPFFER CELLS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXIDES; PROGNOSIS; TISSUE DISTRIBUTION;

EID: 84965091057     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000440629     Document Type: Article

References (32)

1. Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, Takahashi S, Inoue T, Hagiwara S, Chung H, Ueshima K, Maekawa K: Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008; 51:S61-S69.
2. Kudo M, Hatanaka K, Maekawa K: Sonazoidenhanced ultrasound in the diagnosis and treatment of hepatic tumors. J Med Ultrasound 2008; 16: 130-139.
3. Hatanaka K, Kudo M, Minami Y, Maekawa K: Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008; 75(suppl 1):42-47.
4. Inoue T, Kudo M, Hatanaka K, Takahashi S, Kitai S, Ueda T, Ishikawa E, Hagiwara S, Minami Y, Chung H, Ueshima K, Maekawa K: Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoid. Oncology 2008; 75(suppl 1): 48-54.
5. Inoue T, Kudo M, Maenishi O, Komuta M, Nakashima O, Kojiro M, Maekawa K: Value of liver parenchymal phase contrast-enhanced sonography to diagnose premalignant and borderline lesions and overt hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192: 698-705.
6. Kudo M, Hatanaka K, Maekawa K: Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010; 78(suppl 1):40-45.
7. Iijima H: Contrast-enhanced ultrasound in the diagnosis of liver diseases-Tracing the history and perspective (in Japanese). Kanzo 2009; 50: 105-121.
8. Hatanaka K, Minami Y, Kudo M, Inoue T, Chung H, Haji S: The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US. J Clin Ultrasound 2014; 42: 1-8.
9. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX: Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver-update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34: 11-29.
10. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX: Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver-update 2012: A WFUMB-EFSUMB Initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39: 187-210.
11. Inoue T, Kudo M, Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Ueshima K, Nishida N: Usefulness of contrast-enhanced ultrasonography to evaluate the post-Treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology 2013; 84(suppl 1):51-57.
12. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T: Double-contrast ultrasound: A novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 368-370.
13. Hatanaka K, Chung H, Kudo M, Haji S, Minami Y, Maekawa K, Hayaishi S, Nagai T, Takita M, Kudo K, Ueda T, Tatsumi C, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Ueshima K: Usefulness of the post-vascular phase of contrast-enhanced ultrasonography with sonazoid in the evaluation of gross types of hepatocellular carcinoma. Oncology 2010; 78(suppl 1):53-59.
14. Minami Y, Kudo M, Hatanaka K, Kitai S, Inoue T, Hagiwara S, Chung H, Ueshima K: Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: An initial experience. Liver Int 2010; 30: 759-764.
15. Kumada T, Tada T, Kanamori A, Otobe K, Takeshima K: Contrast-enhanced ultrasonography for hepatic tumors (in Japanese). Jpn J Med Ultrasonics 2014; 41: 325-337.
16. Kitaoka M, Kumada T, Matsuda Y, Iijima H, Ogawa M, Kudo N, Kohara K, Konno T, Takakura R, Nishida M, Y. M, Mori H, Yamada M: Ultrasound diagnostic criteria for liver mass (in Japanese). Jpn J Med Ultrasonics 2012; 39: 317-326.
17. Sugimoto K, Shiraishi J, Moriyasu F, Saito K, Doi K: Improved detection of hepatic metastases with contrast-enhanced low mechanical-index pulse inversion ultrasonography during the liver-specific phase of sonazoid: observer performance study with JAFROC analysis. Acad Radiol 2009; 16: 798-809.
18. Moriyasu F, Itoh K: Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol 2009; 193: 86-95.
19. Tada T, Kumada T, Toyoda H, Kiriyama S, Takeshima K, Ogawa S, Otobe K, Nakano M: Diagnosis of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane and enhanced magnetic resonance imaging with GD-EOB-DTPA (in Japanese). Kanzo 2010; 51: 99-106.
20. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; the Liver Cancer Study Group of Japan: JSH consensus-based clinical practice guideline for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014; 3: 458-468.
21. Kudo M: Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer 2013; 2: 69-72.
22. Murakami T, Tsurusaki M: Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer 2014; 3: 85-96.
23. Ichikawa T, Sano K, Morisaka H: Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014; 3: 97-107.
24. Tobe K, Tsuchiya T, Fujiwara J, Yamda G, Nagashima H, Sasaoka K, Mimura H, Motoi M: Kupffer cells well-differentiated tissue of hepatocellular carcinoma (in Japanese). Kanzo 1985; 26: 630-637.
25. Sugihara S, Nakashima O, Kiyomatsu K, Edamitsu O, Kojiro M: Pathomorphologic study on macrophages in hepatocellular carcinoma (in Japanese). Kanzo 1990; 31: 12-18.
26. Goto K: Localization of CD68-positive cells in nodular lesions of the liver (in Japanese). Kanzo 1997; 38: 19-26.
27. Semelka RC, Hussain SM, Marcos HB, Woosley JT: Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings-initial observations. Radiology 2000; 215: 89-94.
28. Gabata T, Matsui O, Terayama N, Kobayashi S, Sanada J: Imaging diagnosis of hepatic metastases of pancreatic carcinomas: significance of transient wedge-shaped contrast enhancement mimicking arterioportal shunt. Abdom Imaging 2008; 33: 437-443.
29. Uchida T: New Liver Pathology. Tokyo, Tyugai-Igakusya, 1999, pp 503-510.
30. Seneterre E, Taourel P, Bouvier Y, Pradel J, Van Beers B, Daures JP, Pringot J, Mathieu D, Bruel JM: Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996; 200: 785-792.
31. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242.
32. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520.